Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.

ABSTRACT: Acutely ill medical patients are at risk of venous thromboembolism (VTE) and VTE-related mortality during hospitalization and posthospital discharge, but widespread adoption of extended thromboprophylaxis has not occurred. We analyzed a subpopulation within the MAGELLAN study of extended thromboprophylaxis with rivaroxaban to reevaluate the benefit risk profile. We identified 5 risk factors for major and fatal bleeding after a clinical analysis of the MAGELLAN study and analyzed efficacy and safety with these patients excluded (n = 1551). Risk factors included: active cancer, dual antiplatelet therapy at baseline, bronchiectasis/pulmonary cavitation, gastroduodenal ulcer, or bleeding within 3 months before randomization. We evaluated efficacy, safety, and benefit risk using clinically comp

SUBMITTER: Spyropoulos AC 

PROVIDER: S-EPMC7019408 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature